Author:
Selen Arzu,Müllertz Anette,Kesisoglou Filippos,Ho Rodney J. Y.,Cook Jack A.,Dickinson Paul A.,Flanagan Talia
Publisher
Springer Science and Business Media LLC
Reference128 articles.
1. Selen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, et al. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. J Pharm Sci. 2014;103:3377–97.
2. Dickinson PA, Kesisoglou F, Flanagan T, Martinez MN, Mistry HB, Crison JR, Polli JE, Cruañes MT, Serajuddin ATM, Müllertz A, Cook JA, Selen A. Optimizing clinical drug product performance: applying biopharmaceutics risk assessment roadmap (BioRAM) and the BioRAM scoring grid. J Pharm Sci 2016;105(11):3243–3255. doi: https://doi.org/10.1016/j.xphs.2016.07.024. Epub 2016 Sep 19.
3. Selen A, Cruañes MT, Müllertz A, Dickinson PA, Cook JA, Polli JE, et al. Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J. 2010;12(3):465–72. https://doi.org/10.1208/s12248-010-9206-0.
4. Flanagan, T. 2018. “The use biopharmaceutics risk assessment to guide product development”. AAPS PharmSci360, Washington DC.
5. Selen A. Pediatric formulations and dosage forms: application of biopharmaceutics risk assessment roadmap (BioRAM). In:11th World Meeting on Pharmaceutics. Biopharmaceutics and Pharmaceutical Technology, Granada: Spain; 2018.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献